Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Stilbazium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | APP | P05067 | 3/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stilbazium SCHEMBL636482 | 1.00 | SNCA (0.47) | SNCAMAPTAPPPTGS2ACHE | |
| Stilbazium SCHEMBL6446924 | 0.99 | MAPT (0.46) | SNCAMAPTAPPPTGS2ACHE | |
| Stilbazium SCHEMBL710325 | 0.97 | MAPT (0.44) | SNCAMAPTAPPPTGS2ACHE | |
| Stilbazium SCHEMBL710326 | 0.97 | MAPT (0.44) | SNCAMAPTAPPPTGS2ACHE | |
| SCHEMBL14139607 | 0.87 | ACHE (0.54) | MAPTACHEALDH1A1KDM4EESR1 | |
| SCHEMBL10068871 | 0.87 | ACHE (0.54) | MAPTAPPACHEALDH1A1SMN1; SMN2 | |
| SCHEMBL13111102 | 0.83 | L3MBTL3 (0.40) | SNCAMAPTAPPPTGS2L3MBTL1 | |
| Stilbazium SCHEMBL710711 | 0.82 | ESR1 (0.43) | MAPTPTGS2ACHEALDH1A1SMN1; SMN2 | |
| Stilbazium SCHEMBL710710 | 0.82 | ESR1 (0.43) | MAPTPTGS2ACHEALDH1A1SMN1; SMN2 | |
| SCHEMBL14536918 | 0.82 | SNCA (0.54) | SNCAMAPTAPPPTGS2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260053963-A1 | RADIOCONJUGATES TARGETING CD33 IN THE TREATMENT OF BREAST CANCER | ACTINIUM PHARMACEUTICALS, INC. | 2026-02-26 | — | — | US | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12539340-B2 | Radioconjugates targeting CD33 in the treatment of cancers | ACTINIUM PHARMACEUTICALS, INC. | 2026-02-03 | — | — | US | disclosed |
| US-12491274-B2 | Radioconjugates targeting CD33 in the treatment of sarcomas | ACTINIUM PHARMACEUTICALS, INC. | 2025-12-09 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-4153723-A | ANILINOMETHYLENEMALONONITRILES | CIBA-GEIGY CORPORATION (US) | 1979-05-08 | — | — | US | disclosed |
| US-4151298-A | ANILINOMETHYLENEMALONONITRILE DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1979-04-24 | — | — | US | disclosed |
| US-4001254-A | ISOTHIOCYANOPYRIDINE DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-3987181-A | CERTAIN 2-TRIFLUOROMETHYLBENZIMIDAZOLES AS ANTHELMINTICS | CIBA-GEIGY CORPORATION (US) | 1976-10-19 | — | — | US | disclosed |
| US-3934017-A | Anthelmintic composition and method utilizing isothiocyanobenzazoles active ingredients | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | ACHE 49/4885SNCA 154/4885MAPT 97/4885 |
| US-12491274-B2 | Radioconjugates targeting CD33 in the treatment of sarcomas | CD22, CD2, ERBB4 | ACHE 3296/4885SNCA 4208/4885MAPT 2597/4885 |
| US-12539340-B2 | Radioconjugates targeting CD33 in the treatment of cancers | CD47, ERBB3, ERBB2 | ACHE 2587/4885SNCA 1952/4885MAPT 2021/4885 |
| US-20260053963-A1 | RADIOCONJUGATES TARGETING CD33 IN THE TREATMENT OF BREAST CANCER | CD22, ERBB3, CD47 | ACHE 2845/4885SNCA 4598/4885MAPT 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.